Compare Las Vegas Sands Corp. (LVS) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: Las Vegas Sands Corp. is far larger — about 10.3× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| LVS | SLS | |
|---|---|---|
Market Cap | $23.38B | $2.27B |
Volume | 6,994,661 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $15.46 |
52-Week Low | $35.81 | $1.39 |
Typical Hold Time | 72 Days | — |
Enterprise Value | $35.27B | $2.14B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.10, up 0.81% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with $13.02B revenue, 12.59% net margin, and positive cash flow of $191M in 2025. Recent news highlights Sands China's community initiatives and operational milestones, while analyst consensus remains strongly bullish with a $59.78 price target.
LVS presents a compelling value opportunity with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). However, high debt levels and recent Q2 2026 earnings miss pose risks. The significant upside to analyst targets suggests potential for substantial returns if operational execution improves.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
